+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Artificial Intelligence in Drug Discovery Market by Technology, Therapeutic Area, Application, End User, Deployment Mode - Global Forecast 2026-2032- Product Image
Artificial Intelligence in Drug Discovery Market by Technology, Therapeutic Area, Application, End User, Deployment Mode - Global Forecast 2026-2032- Product Image
Sale

Artificial Intelligence in Drug Discovery Market by Technology, Therapeutic Area, Application, End User, Deployment Mode - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4995111
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Artificial Intelligence in Drug Discovery Market is projected to reach USD 2.46 Billion in 2026. It is expected to continue growing at a CAGR of 18.12%, reaching USD 6.71 Billion by 2032.

Artificial intelligence in drug discovery has moved from experimental use cases to a core R&D capability across target identification, hit discovery, lead optimization, ADMET prediction, biomarker discovery, and clinical trial design. The shift is supported by validated scientific milestones, including the AlphaFold Protein Structure Database covering more than 200 million predicted protein structures, the U.S. FDA’s ongoing work on AI and machine learning in drug development, and the growing use of high-performance cloud computing in life sciences.

For pharmaceutical companies, biotechnology firms, contract research organizations, and technology partners, AI is not a replacement for biology, chemistry, or clinical evidence. Its strongest value is in compressing hypothesis cycles, improving decision quality, and prioritizing compounds and patient populations before expensive wet-lab or clinical investments are made.

Transformative Shifts in the AI Drug Discovery Landscape

The drug discovery landscape is shifting from sequential, lab-intensive workflows to integrated computational-experimental models. Generative AI, graph neural networks, natural language processing, and multimodal foundation models are helping researchers analyze chemical libraries, omics datasets, protein structures, publications, patents, and real-world data at scale.

Regulatory and operating models are also changing. The U.S. FDA, EMA, and other agencies are increasing attention on model transparency, validation, data provenance, and risk management. At the same time, cloud infrastructure, secure data collaboration, and automation are enabling pharmaceutical R&D teams to evaluate more hypotheses while maintaining traceability and reproducibility.

Cumulative Impact of Artificial Intelligence on Drug R&D

The cumulative impact of artificial intelligence is most visible in earlier and more evidence-driven decision-making. AI-enabled platforms can help identify disease-relevant targets, screen virtual compound libraries, forecast toxicity, optimize molecular properties, and support patient stratification. These applications reduce avoidable experimentation and improve the quality of candidates moving into validation.

However, AI does not eliminate scientific uncertainty. Drug attrition remains driven by complex biology, safety, efficacy, manufacturability, and clinical execution. The organizations gaining the greatest advantage are those combining high-quality proprietary data, rigorous model governance, laboratory validation, and cross-functional teams spanning biology, chemistry, informatics, clinical development, and regulatory affairs.

Key Regional Insights: North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa

North America leads AI-enabled drug discovery through a dense ecosystem of pharmaceutical companies, AI-native biotechnology firms, academic medical centers, cloud providers, venture capital, and regulatory engagement. The United States benefits from NIH-funded biomedical research, FDA digital health and AI initiatives, and a large clinical trial infrastructure, while Canada’s long-standing AI research base and biomedical clusters strengthen translational innovation.

Europe is advancing through strong public research, biopharmaceutical manufacturing, and regulatory modernization, including the EU AI Act and European Health Data Space framework. Asia-Pacific is scaling rapidly, with China, Japan, India, South Korea, Singapore, and Australia investing in genomics, precision medicine, computational biology, and biomanufacturing. Latin America is emerging through Brazil and Mexico’s clinical research capacity, public health datasets, and pharmaceutical manufacturing foundations, while the Middle East is investing in genomics, digital health, and precision medicine through national strategies in the UAE, Saudi Arabia, and other Gulf economies. Africa’s opportunity is tied to genomic diversity, infectious disease research, local biobank development, and capacity-building programs that can improve global model generalizability and reduce data bias in AI drug discovery.

Key Group Insights: EU, G7, BRICS, ASEAN, GCC, and NATO

The European Union is becoming a reference market for trustworthy AI in life sciences, combining advanced research networks with strict rules on data protection, clinical evidence, and algorithmic accountability. G7 countries continue to shape global standards through pharmaceutical R&D intensity, academic excellence, intellectual property systems, regulatory science coordination, and cross-border collaboration on health security.

BRICS economies are strategically important because of their population scale, expanding clinical research networks, manufacturing capacity, and increasing investment in AI, genomics, and biotechnology. ASEAN is gaining relevance through Singapore-led biomedical innovation, regional digital health adoption, and growing clinical research activity across Southeast Asia, while the GCC is using national health transformation programs, population genomics initiatives, and advanced hospital infrastructure to accelerate precision medicine. NATO member countries also influence the sector indirectly through biosecurity, resilient supply chains, cybersecurity, trusted data infrastructure, and dual-use technology governance that affect AI-enabled biomedical innovation.

Key Country Insights Across Major AI Drug Discovery Markets

The United States remains the most influential country for AI in drug discovery due to its concentration of pharmaceutical R&D, venture-backed AI biotechnology companies, FDA engagement, NIH-supported biomedical research, and leading academic medical centers. Canada contributes world-class machine learning expertise and translational AI hubs, while Mexico and Brazil strengthen the Americas through clinical research access, pharmaceutical production capabilities, public health institutions, and growing digital health adoption.

In Europe, the United Kingdom combines biomedical research excellence, national health data assets, and a strong AI startup ecosystem; Germany leads in pharmaceutical manufacturing, engineering, applied research, and industrial automation; France supports AI and health innovation through national investment programs and biomedical research networks; Italy and Spain offer strong clinical trial networks, hospital systems, and translational medicine capabilities; and Russia retains scientific capacity in chemistry, mathematics, and computational research despite geopolitical and collaboration constraints. In Asia-Pacific, China’s scale in data infrastructure, AI investment, genomics, and biopharma innovation is significant; India combines pharmaceutical manufacturing, digital public infrastructure, bioinformatics talent, and software engineering depth; Japan offers advanced precision medicine, robotics, and aging-related biomedical research capabilities; Australia has strong clinical research, genomics programs, and biomedical science institutions; and South Korea is expanding rapidly through government-backed biohealth, hospital digitalization, semiconductor strength, and AI initiatives.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize AI use cases with measurable scientific and operational value, such as target validation, virtual screening, toxicity prediction, protein structure analysis, biomarker discovery, and trial enrichment. Building a defensible advantage requires proprietary datasets, interoperable data architecture, model validation protocols, bias monitoring, cybersecurity controls, and clear documentation aligned with regulatory expectations.

Should also invest in human-AI operating models. The highest-performing organizations embed computational scientists with medicinal chemists, biologists, clinicians, and regulatory experts. Partnerships with AI biotechnology firms, cloud providers, universities, and CROs should be structured around data rights, reproducibility, auditability, model ownership, privacy protection, and milestone-based outcomes rather than technology adoption alone.

Research Methodology

This executive summary is based on a structured secondary research approach using verified public information from regulatory agencies, scientific institutions, government programs, peer-reviewed literature, public disclosures, and recognized life sciences databases. Key themes were triangulated across AI drug discovery workflows, regional innovation systems, regulatory developments, scientific adoption, and investment patterns.

The analysis emphasizes evidence-backed trends rather than speculative market claims. It evaluates how artificial intelligence is applied across discovery and development, where adoption is strongest, which regional ecosystems are gaining momentum, and what governance practices are needed to convert computational insights into validated therapeutic progress.

Conclusion: AI as a Strategic Engine for Modern Drug Discovery

Artificial intelligence is becoming a durable capability in drug discovery because it improves the speed, scale, and precision of scientific decision-making. Its greatest value is achieved when computational models are connected to reliable biological data, laboratory validation, clinical insight, and disciplined governance.

The landscape will be shaped by organizations that can combine AI innovation with regulatory credibility, proprietary data, and therapeutic domain expertise. As adoption expands across regions and industry groups, AI-enabled drug discovery is expected to remain one of the most important forces modernizing pharmaceutical R&D.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Artificial Intelligence in Drug Discovery Market, by Technology
7.1. Computer Vision
7.2. Deep Learning
7.3. Machine Learning
7.4. Natural Language Processing
8. Artificial Intelligence in Drug Discovery Market, by Therapeutic Area
8.1. Cardiovascular Diseases
8.2. Central Nervous System
8.3. Infectious Diseases
8.4. Oncology
9. Artificial Intelligence in Drug Discovery Market, by Application
9.1. ADMET & Toxicology Prediction
9.1.1. Pharmacodynamics Prediction
9.1.2. Pharmacokinetics Prediction
9.1.3. Toxicity Prediction
9.2. Clinical Trial Optimization
9.2.1. Patient Recruitment
9.2.2. Trial Design Optimization
9.3. Hit Identification
9.3.1. High Throughput Screening
9.3.2. In Silico Target Validation
9.3.3. Virtual Screening
9.4. Lead Optimization
9.4.1. De Novo Drug Design
9.4.2. Quantitative Structure Activity Relationship
9.4.3. Structure Based Drug Design
9.5. Protein Structure Prediction
9.5.1. Ab Initio Modeling
9.5.2. Homology Modeling
9.5.3. Molecular Dynamics Simulation
10. Artificial Intelligence in Drug Discovery Market, by End User
10.1. Academic & Research Institutes
10.2. Biotechnology Companies
10.3. Contract Research Organizations
10.4. Pharmaceutical Companies
11. Artificial Intelligence in Drug Discovery Market, by Deployment Mode
11.1. Cloud Based
11.2. Hybrid
11.3. On Premises
12. Asia-Pacific Artificial Intelligence in Drug Discovery Market
13. Europe Artificial Intelligence in Drug Discovery Market
14. North America Artificial Intelligence in Drug Discovery Market
15. Latin America Artificial Intelligence in Drug Discovery Market
16. Africa Artificial Intelligence in Drug Discovery Market
17. Middle East Artificial Intelligence in Drug Discovery Market
18. NATO Artificial Intelligence in Drug Discovery Market
19. G7 Artificial Intelligence in Drug Discovery Market
20. BRICS Artificial Intelligence in Drug Discovery Market
21. European Union Artificial Intelligence in Drug Discovery Market
22. ASEAN Artificial Intelligence in Drug Discovery Market
23. GCC Artificial Intelligence in Drug Discovery Market
24. China Artificial Intelligence in Drug Discovery Market
25. United States Artificial Intelligence in Drug Discovery Market
26. Japan Artificial Intelligence in Drug Discovery Market
27. India Artificial Intelligence in Drug Discovery Market
28. Germany Artificial Intelligence in Drug Discovery Market
29. United Kingdom Artificial Intelligence in Drug Discovery Market
30. Australia Artificial Intelligence in Drug Discovery Market
31. France Artificial Intelligence in Drug Discovery Market
32. South Korea Artificial Intelligence in Drug Discovery Market
33. Italy Artificial Intelligence in Drug Discovery Market
34. Canada Artificial Intelligence in Drug Discovery Market
35. Russia Artificial Intelligence in Drug Discovery Market
36. Brazil Artificial Intelligence in Drug Discovery Market
37. Mexico Artificial Intelligence in Drug Discovery Market
38. Spain Artificial Intelligence in Drug Discovery Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. AbCellera
40.2. Atomwise Inc
40.3. BenchSci
40.4. BenevolentAI
40.5. BioAge Labs
40.6. Bpgbio Inc
40.7. Deep Genomics
40.8. Envisagenics
40.9. Evaxion Biotech A/S
40.10. Generate Biomedicines
40.11. Genesis Therapeutics
40.12. Iambic Therapeutics
40.13. Iktos
40.14. Insilico Medicine
40.15. Insitro
40.16. Nimbus Therapeutics
40.17. NuMedii Inc
40.18. Owkin Inc
40.19. Recursion Pharmaceuticals
40.20. Schrödinger Inc
40.21. Standigm Inc
40.22. Terray Therapeutics
40.23. Valo Health
40.24. Verge Genomics
40.25. XtalPi Inc
List of Figures
FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. ITALY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL COMPUTER VISION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL COMPUTER VISION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL COMPUTER VISION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL DEEP LEARNING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL DEEP LEARNING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL DEEP LEARNING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MACHINE LEARNING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MACHINE LEARNING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MACHINE LEARNING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NATURAL LANGUAGE PROCESSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NATURAL LANGUAGE PROCESSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NATURAL LANGUAGE PROCESSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ADMET & TOXICOLOGY PREDICTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ADMET & TOXICOLOGY PREDICTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ADMET & TOXICOLOGY PREDICTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PHARMACODYNAMICS PREDICTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PHARMACODYNAMICS PREDICTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PHARMACODYNAMICS PREDICTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PHARMACOKINETICS PREDICTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PHARMACOKINETICS PREDICTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PHARMACOKINETICS PREDICTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL TOXICITY PREDICTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL TOXICITY PREDICTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL TOXICITY PREDICTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CLINICAL TRIAL OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CLINICAL TRIAL OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CLINICAL TRIAL OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PATIENT RECRUITMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PATIENT RECRUITMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PATIENT RECRUITMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL TRIAL DESIGN OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL TRIAL DESIGN OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL TRIAL DESIGN OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL HIT IDENTIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL HIT IDENTIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL HIT IDENTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL IN SILICO TARGET VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL IN SILICO TARGET VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL IN SILICO TARGET VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL VIRTUAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL VIRTUAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL VIRTUAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL DE NOVO DRUG DESIGN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL DE NOVO DRUG DESIGN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL DE NOVO DRUG DESIGN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL STRUCTURE BASED DRUG DESIGN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL STRUCTURE BASED DRUG DESIGN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL STRUCTURE BASED DRUG DESIGN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PROTEIN STRUCTURE PREDICTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL PROTEIN STRUCTURE PREDICTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL PROTEIN STRUCTURE PREDICTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL AB INITIO MODELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL AB INITIO MODELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL AB INITIO MODELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL HOMOLOGY MODELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL HOMOLOGY MODELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL HOMOLOGY MODELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL MOLECULAR DYNAMICS SIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL MOLECULAR DYNAMICS SIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL MOLECULAR DYNAMICS SIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL CLOUD BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL CLOUD BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL CLOUD BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL HYBRID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL HYBRID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL HYBRID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL ON PREMISES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL ON PREMISES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL ON PREMISES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 126. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 128. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 129. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 130. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 131. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 132. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 133. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 134. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 135. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 159. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 160. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 161. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 162. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 163. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 164. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 165. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 166. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 167. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 168. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 181. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 182. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 183. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 184. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 185. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 186. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 187. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 188. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 189. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 190. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 192. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 193. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 194. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 195. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 196. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 197. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 198. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 199. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 200. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 201. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 203. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 204. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 205. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 206. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 207. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 208. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 209. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 210. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 211. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 212. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 225. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 226. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 227. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 228. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 229. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 230. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 231. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 232. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 233. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 234. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 235. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 236. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 237. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 238. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 239. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 240. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 241. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 242. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 243. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 244. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 245. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 246. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 247. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 248. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 249. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 250. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 251. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 252. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 253. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 254. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 255. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 256. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 257. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 258. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 264. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 267. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 269. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 270. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 271. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 272. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 273. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 274. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 275. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 276. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 277. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 278. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 279. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 280. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 281. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 282. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 283. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 284. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 285. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 286. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 287. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 288. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 289. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 290. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 291. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 292. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 293. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 294. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 295. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
TABLE 296. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 297. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
TABLE 298. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
TABLE 299. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
TABLE 300. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 301. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
TABLE 302. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE,

Companies Mentioned

The companies featured in this Artificial Intelligence in Drug Discovery market report include:
  • AbCellera
  • Atomwise Inc
  • BenchSci
  • BenevolentAI
  • BioAge Labs
  • Bpgbio Inc
  • Deep Genomics
  • Envisagenics
  • Evaxion Biotech A/S
  • Generate Biomedicines
  • Genesis Therapeutics
  • Iambic Therapeutics
  • Iktos
  • Insilico Medicine
  • Insitro
  • Nimbus Therapeutics
  • NuMedii Inc
  • Owkin Inc
  • Recursion Pharmaceuticals
  • Schrödinger Inc
  • Standigm Inc
  • Terray Therapeutics
  • Valo Health
  • Verge Genomics
  • XtalPi Inc

Table Information

Report AttributeDetails
No. of Pages195
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.46 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.71 Billion
Compound Annual Growth Rate18.1%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Generative AI in Drug Discovery Market Report 2026 - Product Image

Generative AI in Drug Discovery Market Report 2026

  • Report
  • 250 Pages
  • Global
From
AI-Assisted Drug Discovery Software Market - Global Forecast 2025-2030 - Product Image

AI-Assisted Drug Discovery Software Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Artificial Intelligence in Drug Discovery Market Insights, Analysis and Forecast 2026-2031 - Product Image

Artificial Intelligence in Drug Discovery Market Insights, Analysis and Forecast 2026-2031

  • Report
  • 115 Pages
  • Global
From
AI Drug Discovery Software Market - Global Forecast 2025-2030 - Product Image

AI Drug Discovery Software Market - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Artificial Intelligence in Drug Discovery Market Size, Share & Trends Analysis Report by Application, Therapeutic Area, End Use, Region, and Segment Forecasts, 2026-2033 - Product Image

Artificial Intelligence in Drug Discovery Market Size, Share & Trends Analysis Report by Application, Therapeutic Area, End Use, Region, and Segment Forecasts, 2026-2033

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.